Pharmaceutical company engaged in the discovery and development of proprietary prodrugs
Prodrug therapies and improving abuse deterrence and consumer safety
Anti-opioid abuse legislation FDA regulation of opioid abuse deterrent formulations
H.R. 2430 (FDA Reauthorization Act of 2017), provisions relating to drugs
H.R. 2025 (Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017), all provisions
HCR - Health Issues PHA - Pharmacy
34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 19 - Office of Natl Drug Control Policy (NDCP) 1 - SENATE 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 19 - Office of Natl Drug Control Policy (NDCP) 1 - SENATE
ARENTFOX SCHIFF LLP
1717 K Street, NW, Washington, DC, 20006, US
PHILIP ENGLISH NORMAN FREDERICK LENT SONJA NESBIT PHILIP ENGLISH NORMAN FREDERICK LENT